A multidisciplinary program for bronchiectasis and pulmonary NTM disease reduced patient exacerbations by 36% per quarter.
Bronchiectasis hospitalizations have higher mortality and costs than COPD and asthma, with a median stay of 5 days and costs of $50,393. During the COVID-19 pandemic, bronchiectasis hospitalizations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results